Trial Profile
A Randomized, Double-Blind, Controlled Phase III Study of Stimuvax (L-BLP25 or BLP25 Liposome Vaccine) in Combination With Hormonal Treatment Versus Hormonal Treatment Alone for First-Line Therapy of Post-Menopausal Women With Estrogen Receptor (ER)-Positive and/or Progesterone Receptor (PgR)-Positive, Inoperable Locally Advanced, Recurrent, or Metastatic Breast Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 07 Apr 2022
Price :
$35
*
At a glance
- Drugs Tecemotide (Primary) ; Cyclophosphamide; Hormones
- Indications Advanced breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms STRIDE
- Sponsors EMD Serono; Merck KGaA
- 06 Apr 2022 This trial has been completed in Netherland (End Date: 10 Sep 2010), according to European Clinical Trials Database record.
- 31 Mar 2012 Additional locations (Hungary, Sweden, Netherlands, Portugal, Ireland, France, Italy, Greece, Spain) added as reported by European Clinical Trials Database.
- 31 Mar 2012 Planned number of patients changed from 909 to 1200 as reported by European Clinical Trials Database.